Maia Wealth LLC Grows Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Maia Wealth LLC increased its position in IQVIA Holdings Inc. (NYSE:IQV) by 14.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,639 shares of the medical research company’s stock after buying an additional 1,872 shares during the period. Maia Wealth LLC’s holdings in IQVIA were worth $3,030,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of IQV. Nisa Investment Advisors LLC raised its holdings in shares of IQVIA by 4.9% in the 3rd quarter. Nisa Investment Advisors LLC now owns 11,346 shares of the medical research company’s stock worth $2,689,000 after purchasing an additional 530 shares during the period. US Bancorp DE raised its holdings in shares of IQVIA by 62.2% during the 3rd quarter. US Bancorp DE now owns 27,061 shares of the medical research company’s stock valued at $6,413,000 after buying an additional 10,379 shares during the period. Farther Finance Advisors LLC lifted its position in IQVIA by 35.2% during the 3rd quarter. Farther Finance Advisors LLC now owns 407 shares of the medical research company’s stock worth $96,000 after acquiring an additional 106 shares in the last quarter. Chicago Partners Investment Group LLC acquired a new stake in IQVIA in the third quarter valued at approximately $218,000. Finally, Optas LLC purchased a new stake in shares of IQVIA during the third quarter valued at approximately $210,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Stock Up 1.3 %

NYSE:IQV opened at $188.89 on Friday. The firm has a market capitalization of $33.26 billion, a PE ratio of 25.19, a price-to-earnings-growth ratio of 1.99 and a beta of 1.48. IQVIA Holdings Inc. has a 52 week low of $184.66 and a 52 week high of $261.73. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The stock has a 50 day moving average of $199.13 and a 200-day moving average of $214.80.

IQVIA (NYSE:IQV) last issued its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analysts Set New Price Targets

IQV has been the subject of several analyst reports. William Blair restated an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th. JPMorgan Chase & Co. decreased their price objective on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a research report on Tuesday, February 18th. Bank of America dropped their target price on IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a research report on Friday, December 13th. Stephens initiated coverage on IQVIA in a research note on Friday, December 20th. They set an “overweight” rating and a $250.00 price objective for the company. Finally, UBS Group dropped their price objective on IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Four analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, IQVIA presently has an average rating of “Moderate Buy” and an average price target of $251.22.

Insider Buying and Selling at IQVIA

In other IQVIA news, Director John G. Danhakl purchased 1,275 shares of the business’s stock in a transaction dated Tuesday, December 3rd. The shares were bought at an average price of $200.58 per share, with a total value of $255,739.50. Following the completion of the acquisition, the director now owns 1,275 shares in the company, valued at approximately $255,739.50. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.60% of the stock is currently owned by company insiders.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.